• Home
  • NEW DAY MEDICINE
  • 12 (86) 2025
  • 135 -12 (86) 2025 - Kholikov A.Y., Urmanova Y.M. - THE ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

135 -12 (86) 2025 - Kholikov A.Y., Urmanova Y.M. - THE ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

THE ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Kholikov A.Y. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician E.Kh. Turakulova, Ministry of Health of the Republic of Uzbekistan

Urmanova Y.M. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician E.Kh. Turakulova, Ministry of Health of the Republic of Uzbekistan

Khalimova Z.Y. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician E.Kh. Turakulova, Ministry of Health of the Republic of Uzbekistan

Kodirova R.R. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician E.Kh. Turakulova, Ministry of Health of the Republic of Uzbekistan

Resume

The aim of the study was to investigate the significance of C-reactive protein in the development of renal dysfunction in patients with type 2 diabetes mellitus. Material and methods: We examined and surveyed 67 patients with COPD+type 2 diabetes mellitus and stage 1-3 CKD. There were 28 women and 39 men. The average age of men was 57.7 ± 452 years, while the average age of women was 55.6 ± 4.6 years. The control group consisted of 20 patients with type 2 diabetes mellitus without COPD and without CKD of the corresponding age. According to the degree of chronic kidney disease (CKD), the patients were divided into 3 groups: group 1 - 19 (28.3%) patients with stage 1 diabetic nephropathy, group 2 - 28 (41.7%) patients with stage 2 diabetic nephropathy, group 3 - 38 (58.5%) patients with stage 3 diabetic nephropathy, group 4 - 55 (58.5%) patients with stage 4 diabetic nephropathy, group 5 - 55 (58.5%) patients with stage 5 diabetic nephropathy, group 6 - 55 (58.5%) patients with stage 6 diabetic nephropathy, group 7 - 55 (58.5%) patients with stage 7 diabetic nephropathy, group 8 - 55 (58.5%) patients with stage 8 diabetic nephropathy, group 9 - 55 (58.5%) patients with stage 9 diabetic nephropathy, group 10 - 55 (58.5%) patients with stage 9 diabetic nephropathy, group 11 - 55 (58.5%) patients with stage 9 diabetic nephropathy, group 12 - 55 (58.5%) patients with stage 9 diabetic nephropathy, group 13 - 55 (58.5%) patients with stage 9 diabetic - 20 (29.8%) patients with diabetic nephropathy stage 3. The control group consisted of 20 individuals with type 2 diabetes and without CKD. All 67 patients underwent all examinations, including general clinical, biochemical, hormonal blood tests of the research laboratory of the RSSPMC of Endocrinology of the Ministry of Health of the Republic of Uzbekistan, as well as ECG, ultrasound of internal organs, consultation with a cardiologist, neurologist, nephrologist, ophthalmologist, surgeon, and other studies. Study results. In patients of group 3, a significant increase in fasting glycemia, postprandial glycemia, glycated hemoglobin, blood creatinine (p < 0.05) was found against the background of dyslipidemia (a decrease in HDL, and the lowest SCF. (p < 0.05)). It was shown that in patients with type 2 diabetes and stage 1-3 CKD, a reliable significant correlation was observed between CRP and various indicators: total cholesterol (r=0.49, r=0.54, r=0.59), triglycerides (r=0.48, r=0.55, r=0.58) among patients of the three groups, respectively, statistically significant. Conclusions. In patients with type 2 diabetes and stage 1-3 CKD, a reliable significant correlation was observed between CRP and lipids in all groups, while increasing with increasing renal dysfunction.

Key words: type 2 diabetes + stage 1-3 CKD.

First page

752

Last page

757

For citation:Kholikov A.Y., Urmanova Y.M., Khalimova Z.Y., Kodirova R.R. - THE ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS//New Day in Medicine 12(86)2025 752-757 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

  1. Sun H, Saeedi P, Karuranga S, Pinkepank M, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6. Erratum in: // Diabetes Res Clin Pract. 2023 Oct;204:110945. doi: 10.1016/j.diabres.2023.110945
  2. Saeedi P, Petersohn I, Salpea P, Malanda B, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843.
  3. Valencia W. M., Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control //Bmj. – 2017. – Т. 356.
  4. Lin Y. C. et al. Update of pathophysiology and management of diabetic kidney disease //Journal of the formosan Medical Association. 2018;117(8):662-675.
  5. Chen C, Wang C, Hu C, Han Y, Zhao L, Zhu X, Xiao L, Sun L. Normoalbuminuric diabetic kidney disease. //Front Med. 2017 Sep;11(3):310-318. doi: 10.1007/s11684-017-0542-7.
  6. Hayashino Y, Mashitani T, Tsujii S, Ishii H; Diabetes Distress and Care Registry at Tenri Study Group. Serum high-sensitivity C-reactive protein levels are associated with high risk of development, not progression, of diabetic nephropathy among Japanese type 2 diabetic patients: a prospective cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT7]). //Diabetes Care. 2014 Nov;37(11):2947-52. doi: 10.2337/dc14-1357.
  7. García-García PM, Getino-Melián MA, Domínguez-Pimentel V, Navarro-González JF. Inflammation in diabetic kidney disease. // World J Diabetes. 2014 Aug 15;5(4):431-43. doi: 10.4239/wjd.v5.i4.431.
  8. Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. //J Diabetes Res. 2015;2015:948417. doi: 10.1155/2015/948417.
  9. Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, Kim KR, Lee HC. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. //Diabetes Res Clin Pract. 2005 Aug;69(2):151-9. doi: 10.1016/j.diabres.2004.11.014
  10. Liu Q, Jiang CY, Chen BX, Zhao W, Meng D. The association between high-sensitivity C-reactive protein concentration and diabetic nephropathy: a meta-analysis. //Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4558-68.

    file

    download